SIGNAL // LOADING
Loading page
Glossary term
Zepbound
Also known as Tirzepatide (chronic weight management indication)
Brand-name tirzepatide. FDA-approved for chronic weight management at BMI 30+, or 27+ with a comorbidity.
Zepbound is Eli Lilly's tirzepatide formulation labeled for chronic weight management in adults with BMI 30+ or 27+ with comorbidity. SURMOUNT-1 showed ~20.9% mean weight loss at 72 weeks on the 15 mg dose. Same molecule as Mounjaro, different label. Insurance coverage and supply swing outcomes for many members, which is why the eligibility conversation compares Zepbound, Mounjaro, and compounded tirzepatide side-by-side.
Medically reviewed byDr. Lena Okafor, MD
Medical Director - updated April 2026How we review
External references
Related
Connected context
Related terms
Related guides
GLP-1 eligibility explained: who qualifies, who doesn't, and whyTirzepatide vs semaglutide: how to think about the choiceWhat a comprehensive metabolic panel actually tells youProvider-reviewed care vs DIY supplementation: when each makes sensePCOS labs: the markers that actually drive the planGLP-1 side effects: what's normal, what needs review, what stops the protocolHolding the loss after GLP-1: protein, training, and the maintenance planFasting insulin and HOMA-IR: the metabolic signal that precedes A1c by yearsCreatine, protein, and the two supplements that actually moved your labsWeight-loss plateaus on GLP-1: what to change first